Thomasj Hwang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A new federal law may soon help people taking costly drugs for rheumatologic diseases, some of which may eventually fall subject to Medicare negotiations because of the cost and lack of competition.

Many drugs with accelerated approvals lack 'high added' value compared with other therapies, and conducting further trials of these drugs is financially risky for the manufacturers.